Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormone-Resistant Prostate Cancer Clear all
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
dietary intervention, nutritional support, laboratory biomarker analysis
Dietary Supplement · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 21, 2026, 5:33 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Cancer AJCC v8
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer, Multiple Myeloma, Plasmacytoma
Interventions
sodium selenite, radiation therapy, laboratory biomarker analysis, pharmacological study, questionnaire administration
Drug · Radiation · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
docetaxel, pasireotide, prednisone
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
XL102, Fulvestrant, Abiraterone, Prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Cixutumumab, Diagnostic Laboratory Biomarker Analysis, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Selinexor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment
Dietary Supplement · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Interventions
lorigerlimab, docetaxel, Prednisone
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Castration-resistant Prostate Cancer
Interventions
abiraterone acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
8
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
saracatinib, hydrocortisone/placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer, Recurrent Prostate Cancer
Interventions
Dasatinib
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Duarte, California • Loma Linda, California • Orange, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Fluorine F 18 Sodium Fluoride
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction, enzyme-linked immunosorbent assay, RNA analysis, spectrophotometry, reverse transcriptase-polymerase chain reaction, gene expression analysis
Drug · Other · Genetic
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • Piscataway, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
New Brunswick, New Jersey • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Interventions
ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
10
States / cities
Huntsville, Alabama • Tampa, Florida • Chicago Ridge, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
Doxil and Estramustine
Drug
Lead sponsor
Morton Plant Mease Health Care
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2006 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone, ABT-263, Hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis, Phenelzine Sulfate
Procedure · Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer
Interventions
TRX518, Cyclophosphamide, Avelumab
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ZD4054, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
25
States / cities
Greenbrae, California • San Diego, California • Norwich, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced May 21, 2026, 5:33 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, Blood draws
Drug · Other
Lead sponsor
Saladax Biomedical, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Beaver, Pennsylvania • Bethel Park, Pennsylvania • Farrell, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced May 21, 2026, 5:33 PM EDT